Interferon-tau (IFNT) is the trophoblast-secreted factor responsible for establishing and maintaining pregnancy in ruminants. Several uterine-and embryo-derived factors, including fibroblast growth factor-2 (FGF2), regulate IFNT production. The objective of the present study was to decipher the intracellular signaling mechanisms employed by FGF2 to regulate IFNT production. In bovine trophoblast cells (CT1), mitogen-activated protein kinase kinase-dependent pathways mediated constitutive IFNT mRNA concentrations. However, FGF2-mediated increases in IFNT mRNA levels occurs independent of mitogen-activated protein kinase. Exposure to the panprotein kinase C (PKC) inhibitor, calphostin C, did not affect basal IFNT mRNA levels but limited the ability of FGF2 to increase IFNT mRNA abundance. Also, supplementation with phorbol 12-myristate 13-acetate (PMA) stimulated IFNT mRNA levels to the same extent as with FGF2. PMA and FGF2 cosupplementation did not elicit an additive effect on IFNT mRNA abundance. Pharmacological antagonists for classic PKCs (Gö 6976) or novel PKCs, including PKC delta (rottlerin), were used to identify the specific PKC isoform utilized by FGF2. Supplementation of CT1 cells with Gö 6976 did not affect FGF2 or PMA activities, whereas rottlerin prevented FGF2-and PMAdependent increases in IFNT mRNA abundance in CT1 cells. Rottlerin also prevented FGF2 from increasing IFNT mRNA levels in Vivot trophoblast cells and primary trophoblast outgrowths. Modifications in PRKCD phosphorylation status were evident following FGF2 and PMA treatment. Also, reducing PRKCD expression by RNA interference attenuated FGF2-dependent increases in IFNT mRNA abundance. In conclusion, these results provide evidence that FGF2 regulates IFNT production in bovine trophectoderm by acting through PRKCD.
INTRODUCTION
Interferon-tau (IFNT) is the trophectoderm-secreted factor responsible for establishing and maintaining early pregnancy in cattle, sheep, goats, deer, and likely other ruminants as well [1, 2] . IFNT is best known as an antiluteolytic agent. It prevents luteolysis by limiting the pulsatile release of endometrial prostaglandin F 2a production [1, 2] . IFNT also stimulates endometrial prostaglandin E 2 synthesis, a putative luteotrophic agent [3, 4] . More recently, IFNT has been linked to additional activities, such as inducing uterine factors that promote conceptus development [5] [6] [7] , increasing endometrial glucose and amino acid transporter expression [8, 9] , regulating uterine and systemic immune responses to pregnancy [10, 11] , and impacting gene expression in the corpus luteum (CL) [12, 13] . It is not surprising that miscues in IFNT production and action are linked with pregnancy failures in cattle [14] [15] [16] .
Dynamic changes in IFNT production occur as the conceptus develops and elongates before uterine attachment. Bovine embryos begin producing IFNT at the morula and blastocyst stages coincident with trophoblast lineage specification [17, 18] . The relative abundance of IFNT transcripts and protein increases dramatically at Days 14 and 15 of pregnancy as conceptus elongation begins [19, 20] . Expression decreases abruptly as trophectoderm attaches to the uterine epithelium on or after Day 21 of pregnancy [19, 21] . Exposure to viruses or other pathogens do not impact IFNT expression as they do for most other type I interferons [22, 23] . Instead, IFNT transcription is controlled developmentally by at least two trophoblast-specifying transcription factors (CDX2 and DLX3) and by ETS2, a member of a family of transcriptional regulators involved with various cellular activities [24] [25] [26] [27] .
Over the past several years, it has become clear that several fibroblast growth factors (FGFs) regulate IFNT production in bovine trophoblast cells and blastocysts [28] [29] [30] . Multiple FGFs exist in mammals, and most serve as paracrine-acting regulators of proliferation, differentiation, morphogenesis, and angiogenesis during embryonic, fetal, and postnatal development [31] . Several FGFs are produced by the bovine conceptus and uterus before implantation. Most uterine-derived FGFs are produced within the endometrial stroma or smooth muscle layers surrounding local blood vessels [32, 33] and may not reach the uterine lumen to influence conceptus development before implantation. However, FGF2 is produced by luminal and glandular epithelium and released into the uterine lumen throughout early pregnancy in sheep and cattle [29, 34] . Elevated quantities of FGF2 protein are released into the uterine lumen coincident with conceptus elongation and maximal IFNT expression in sheep [34] . Bovine conceptuses also produce several FGFs, most notably FGF2 and FGF10, before implantation [28] .
Several FGF receptors (FGFRs) also exist in bovine and ovine conceptuses [28, 34] . Four genes encode tyrosine kinase receptors (FGFR1 through FGFR4) [31, 35] , and transcripts for each FGFR exist in ovine and bovine conceptuses at the blastocyst stage (Days 7 and 8 postinsemination) and thereafter [28, 34] . It is unclear how FGFs regulate IFNT production. ETS2 activity is crucial for IFNT transcription, and maximal ETS2 activity requires tyrosine phosphorylation within its pointed domain. A RAS-mediated mitogen-activated protein kinase (MAPK) pathway controls this phosphorylation event [25, 26] . Protein kinase A (PKA) and protein kinase C (PKC) also regulate IFNT transcription. Stimulating PKA activity with dibutyryl cAMP increases IFNT promoter/enhancer activity [36] . Similarly, exposure to phorbol ester, a diacylglycerol (DAG) mimic and PKC activator, increases IFNT mRNA concentrations in ovine conceptus explants and stimulates IFNT promoter/enhancer activity in various human cell lines [37, 38] .
The overall goal of the present study was to describe the signaling mechanisms used by FGF2 to regulate IFNT production. This report provides evidence that PRKCD, a member of the novel PKC subfamily, mediates IFNT mRNA abundance during early pregnancy in bovine trophectoderm. The PKCs are grouped within three subfamilies based on structural similarities and commonality of responses to various stimuli [39] . Classical PKCs (a, bI, bII, and c) are activated by various stimuli, including Ca 2þ , DAG, and phorbol esters, whereas novel PKCs (d, h, e, and g) are not Ca 2þ dependent but, rather, are responsive to DAG and phorbol esters. The third subfamily, termed atypical PKCs, represents lipiddependent kinases that are not controlled by Ca 2þ or phorbol esters. Identifying a role for PRKCD in bovine trophoblast cells provides new insight regarding the mechanisms controlling early conceptus development in this species and offers another function for this signal transducer molecule.
MATERIALS AND METHODS

Materials
Dulbecco modified essential medium containing high glucose (DMEM), Opti-MEM, fetal bovine serum (FBS), insulin/transferrin/selenium solution (ITS), cell culture supplements, PCR primers, small interfering (si) RNAs, TRIzol, PureLink Total RNA Purification System, SuperScript III First Stand Synthesis kit, ThermalAce DNA Polymerase, pCR-Blunt TOPO vector, and Cy3-labeled control siRNA were purchased from Invitrogen Corp. HiPerFect siRNA transfection reagent was purchased from Qiagen Sciences. Matrigel was purchased from BD Biosciences. RNase-free DNase was purchased from New England Biolabs. Pharmacological inhibitors for MAPK2 (MEK; U0126 and PD98059), PKCs (calphostin C, Gö6976, and rottlerin), phorbol 12-myristate 13-acetate (PMA), and 4a-PMA were purchased from EMD Chemicals. The FGFR inhibitor, PD173074, was purchased from Stemgent. All antibodies were purchased from Cell Signaling Technology. The High Capacity cDNA Reverse Transcription kit and SYBR Green Detector System were purchased from Applied Biosystems, Inc. Polyvinylidene difluoride (PVDF; Immobilon-P) membrane was purchased from Millipore Co. Enhanced chemiluminescence (ECL) Western blot detection system was purchased from Amersham (GE Healthcare). The Cell Titer 96 Aqueous One Solution Cell Proliferation Assay was purchased from Promega Corp. Recombinant human IFNA standard was purchased from EMD Biosciences. Reagents and materials for superovulation and conceptus collections were purchased from Agtech, Inc. (Waukesha, WI). All other reagents were purchased from Sigma-Aldrich Co. or Thermo Fisher Scientific.
Trophoblast Cell Culture
The CT1 and Vivot bovine trophoblast cell lines were isolated by Talbot et al. [40, 41] . The CT1 line was derived from an in vitro-produced bovine blastocyst, whereas the Vivot line was developed from an in vivo-derived bovine blastocyst [40, 41] . Each cell line was propagated without a feeder cell as described previously [29] on Matrigel-coated plates in DMEM containing 10% (v/v) FBS, 100 lM nonessential amino acids, 55 lM b-mercaptoethanol, and antibioticantimycotic (100 U/ml of penicillin G, 100 lg/ml of streptomycin sulfate, and 250 ng/ml of amphotericin B) at 38.58C with 5% CO 2 in air. Cells were passaged manually by separating them from plates with a cell scraper and dissociating them into small clumps with repeated dissociation through a 20-gauge needle. Cells were then seeded onto 12-or 24-well plates containing Matrigel. After 3 days, medium was removed and replaced with DMEM lacking FBS but containing all other supplements and ITS (10 lg/ml of insulin, 5.5 lg/ml of transferrin, and 6.7 ng/ml of sodium selenite). After 20-22 h, pharmacological inhibitors or vehicle ( 0.01% [v/v] dimethyl sulfoxide [DMSO]) was added. After 2 h, medium was replaced, and cells were supplemented with 50 ng/ml of bovine FGF2 and 100 nM PMA or vehicle (1% bovine serum albumin [BSA]) in fresh serum-free medium. An inactive phorbol ester, 4a-PMA served as a control for PMA in some studies. After 22-24 h of exposure to FGF2 or PMA, total cellular (tc) RNA was extracted using TRIzol and the PureLink Micro-to-Midi Total RNA Purification System.
Primary bovine trophoblast outgrowths were generated from in vitroproduced bovine embryos as described previously with modifications [40] . On Day 8 postfertilization, individual expanded blastocysts were placed in Matrigel-coated wells of 48-well plates with DMEM containing 10% FBS, 100 lM nonessential amino acids, 55 lM b-mercaptoethanol, and antibioticantimycotic. A morphological assessment of was completed on Day 15 after in vitro fertilization (monolayers of tightly packed cells with prominent nuclei and numerous secretory granules; dome formation evident in some outgrowths). On Day 20 postfertilization, trophoblast outgrowths were scraped and dissociated manually. Outgrowths were pooled together within each replicate study (n ¼ 3 replicates) and used to seed 12-well plates containing Matrigel. After 4-5 days, outgrowths were serum starved, and treatments were supplemented as described for CT1 and Vivot cells.
Quantitative Real-Time RT-PCR
Total cellular RNA concentration and purity were determined using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). Samples (10 ng of tcRNA; A 260 :A 280 ratio, !1.8) were incubated with RNase-free DNase for 30 min at 378C. After heat-inactivating the DNase (758C for 10 min), RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription kit and random hexamers. Primers (200 nM) specific for IFNT, PRKCD (gene abbreviation for PKCd), PRKCQ (gene abbreviation for PKCh), or 18S (internal control) ( Table 1) were used in combination with a SYBR Green Detector System and a 7300 Real-Time PCR System (Applied Biosystems, Inc.) to quantify target gene abundance [28, 29] . A dissociation-curve analysis (60-958C) was used to verify the amplification of a single product. Each sample was completed in triplicate reactions. A fourth reaction lacking reverse transcriptase was included to control for genomic DNA contamination. Standard curves generated from serial dilutions of bovine conceptus tcRNA collected on Day 17 of pregnancy [28] were used to determine IFNT primer efficiency (94%). The comparative threshold cycle (C T ) method was used to quantify mRNA abundance [29] . The average DC T value for each sample was calculated (C T for gene of interest À C T for 18S) and used to calculate the foldchange in relative abundance of each transcript.
Western Blot Analyses
CT1 cells were seeded onto six-well plates containing Matrigel. After 3 days, medium was removed and replaced with DMEM lacking FBS but containing all other supplements and ITS. After 20-22 h, pharmacological inhibitors or carrier only was added. After 2 h, medium was removed and replaced with fresh serum-free medium containing 50 ng/ml of bovine FGF2 or 100 nM PMA. Cells were collected either immediately before (time zero) or at several time points after FGF2 and PMA supplementation. Cells were rinsed in 0.1 M PBS (pH 7.4) and dissolved using NP-40 buffer (20 mM Tris-HCl [pH 8], 137 mM NaCl, 20 mM ethylenediaminetetra-acetic acid, and 1% NP40) supplemented with protease and phosphatase inhibitor cocktails. Cell lysates were sonicated for 15 sec and centrifuged (10 min at 10 000 3 g). Protein concentrations of supernatants were determined using a BCA Protein Assay. 
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In one study, CT1 cells were cultured in serum-free medium without ITS to examine whether the inclusion of these factors impacted MAPK3/1 phosphorylation status. In another study, CT1 cells were treated with 100 nM PD173074, an FGFR kinase inhibitor [42] , or with its carrier only (0.01% DMSO) during serum starvation and FGF2 challenge to examine whether endogenous FGFs impacted MAPK3/1 activity. This concentration of inhibitor effectively blocked FGF2-induced increases in IFNT mRNA abundance in CT1 cells without altering apoptosis rate (Ozawa and Ealy, unpublished observations).
Identical amounts of protein (15-35 lg, depending on the study) were loaded and electrophoresed in 10% or 12% (w/v) SDS-PAGE gels. Samples were electrotransferred onto a PVDF membrane (pore size, 0.45 lm) using a semidry membrane blotter (Amersham Biosciences). Membranes were blocked with 5% (w/v) nonfat dry milk in TBST (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 0.1% Tween-20), then incubated overnight at 48C with total (pan) or phosphospecific MAPK3/1 (T202/Y204; 1:2000) or PKC delta Y311 (1:1000) in TBST containing 3% (w/v) BSA. Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G, ECL, and exposure to BioMax film (Thermo Fisher Scientific) were used to visualize reactive bands. After detection, membranes were washed with TBST and incubated in stripping buffer (2% SDS, 100 mM bmercaptoethanol, and 50 mM Tris-HCl [pH 6.8]) at 508C for 30 min with gentle shaking. For MAPK3/1 studies, blots were blocked and used again so that total and phospho-specific bands could be visualized on the same blot. For PRKCD antisera studies, blots were blocked and incubated in anti-a-tubulin (1:3000). Three independent Western blots generated from different CT1 cultures were completed for each study. Representative blots were photographed for presentation.
Antiviral Activity
CT1 cells were serum-starved for 24 h, then treated with 5 lM rottlerin or carrier only (0.01% DMSO) for 2 h. Medium was exchanged, and cells were cultured in serum-free medium containing either 0 or 50 ng/ml of FGF2 or 0 or 100 nM PMA, depending on the study. After 48 h, medium was conditioned, collected, and stored at À808C. Viable cell number was determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Absorbance at 490 nm was recorded using SpectraMax 340PC384 (Molecular Devices).
The amount of biologically active IFNT in CT1-conditioned medium was determined using an antiviral assay as described previously [34] . The ability of conditioned medium samples to inhibit vesicular stomatitis virus-induced death of Madin-Darby bovine kidney cells by 50% was compared with the activity of recombinant human IFNA standard (3.84 3 10 8 IU antiviral activity/mg protein). The antiviral activity of conditioned media was adjusted based on this standard to represent the IU activity/ml sample. Data also were adjusted to account for potential variations in cell number by normalizing for cell titer readings (A 490 ).
Bovine Conceptus Collection and End-Point RT-PCR
All animal studies were performed in accordance with the guidelines and the approval of the Institutional Animal Care and Use at the University of Florida (UF). Conceptuses were harvested on Days 14 and 17 postinsemination from nonlactating Holstein cows housed at the UF Dairy Unit. Conceptuses were either collected nonsurgically by transcervical uterine flushing (Day 14) or after cows were slaughtered at the UF Meats Laboratory as described previously [28] . Approximately half of the Day 14 conceptuses collected were ovoid. The remaining Day 14 conceptuses were elongated and ranged from 0.5 to 3 cm in length. All of the Day 17 conceptuses were filamentous and ranged from 5 to 45 cm in length. From three to five conceptuses were pooled together and snap-frozen in liquid nitrogen. Each of the Day 14 samples contained at least one ovoid and one elongating conceptus. The CL (n ¼ 3) were collected from ovaries of nonsuperovulated cows at slaughter. All samples were stored at À808C until RNA isolation using TRIzol reagent.
For end-point RT-PCR analysis, tcRNA (500 ng) from CT1, Day 14 and Day 17 conceptuses, and CL were incubated in RNase-free DNase as described previously. Reverse transcription was completed using the SuperScript III First Stand Synthesis kit and random hexamers according to manufacturer's instructions. PCR amplification was completed with primers for PRKCD, PRKCQ, or ACTB (Table 1) using ThermalAce DNA Polymerase (35 cycles of 958C for 1 min, 58-608C for 1 min, and 728C for 1 min, followed by a final extension of 728C for 10 min). Products were electrophoresed in a 1.5% (w/v) agarose gel containing ethidium bromide (100 ng/ml) and visualized under ultraviolet light. Amplicons were cloned into the pCR-Blunt TOPO vector, and inserts were sequenced to verify correctness of amplification at the UF DNA Sequencing Core Facility.
RNA Interference
Three siRNA duplexes were used ( Table 1 ). The siRNA#1 was examined previously in a bovine endothelial cell line [43] , and the siRNA#2 and siRNA#3 were designed using the BLOCK-iT RNAi Designer Program (Invitrogen Corp.) based on the Bos taurus sequence for PRKCD in GenBank (GeneID: 505708). Cy3-labeled control siRNA served as the negative control.
For transfection, Vivot cells were scraped off plates at 30%-40% confluency in Opti-MEM and passed through a 22-gauge needle three to five times before being placed onto Matrigel-coated, 24-well plates (100 ll volume/ well). An siRNA cocktail containing 25 nM of each siRNA was combined with 4.5 ll of HiPerFect siRNA transfection reagent in 100 ll Opti-MEM and incubated at room temperature for 10 min before mixing with Vivot cells. Opti-MEM and siRNA reagents were removed after 9 h and replaced with DMEM containing 10% FBS and other additives. For quantitative RT-PCR studies, cells were serum-starved after 2 days in culture as described previously and then exposed to 50 ng/ml of FGF2 or vehicle only for 24 h before tcRNA extraction. For Western blot analysis, cells were cultured for 3 days before collecting protein lysates.
Statistical Analyses
All analyses were performed by least-squares ANOVA using the general linear model of the SAS software (SAS Institute, Inc.). Fold-differences between real-time analyses were log-transformed to remove heterogeneity of variances [28, 29] . Differences between individual means were contrasted with pairwise analysis (PDIFF [probability of difference] analysis in SAS). Results are presented as the arithmetic mean 6 SEM.
RESULTS
MAPK3/1-Dependent Regulation of IFNT Expression
Ras-mediated pathways regulate IFNT transcription [26] , and the objective of the first set of experiments was to determine if ERK and/or p38-MAPK pathways control constitutive and FGF2-dependent increases in IFNT mRNA levels in bovine trophoblast cells. CT1 cells were exposed to a pharmacological inhibitor of mitogen-activated protein kinase kinase (MAP2K; 10 lM U0126) for 2 h, and then medium was changed and replaced with fresh, serum-free medium supplemented with 0 or 50 ng/ml of FGF2 for 22-24 h. This duration of FGF2 treatment was chosen based on outcomes of preliminary studies. In those studies, FGF2 responses could first be realized after 8-12 h of FGF2 treatment but were maximal after 24 h exposure to FGF2 (data not shown).
Constitutive phosphorylation of MAPK3/1 was evident in CT1 cells, and providing FGF2 did not influence MAPK3/1 phosphorylation status (Fig. 1A) . Supplementation with U0126 abolished constitutive MAPK3/1 phosphorylation, and no MAPK3/1 phosphorylation was observed in the first 2 h after providing FGF2 (Fig. 1A ). Experiments were not completed to examine if MAPK3/1 phosphorylation was interrupted for more than 2 h. Supplementation with U0126 had a major impact on the relative abundance of IFNT mRNA in CT1 cells (Fig. 1B) . As seen in previous reports [28] [29] [30] , FGF2 increased (P , 0.05) the relative abundance of IFNT mRNA in the absence of MAP2K inhibitor. Exposure to the MAP2K inhibitor reduced (P , 0.05) IFNT mRNA levels to below the control value in cells supplemented with 0 or 50 ng/ml of FGF2.
PKC-Dependent Regulation of IFNT Expression
A separate set of experiments was completed to determine if FGF2 utilized PKC-dependent systems to regulate IFNT mRNA abundance in bovine trophoblast cells. Initially, a series of pharmacological PKC inhibitors and mimics were examined.
In the first experiment, supplementing medium with the pan-PKC inhibitor, calphostin C, at a concentration suitable for blocking most PKC isoforms (5 lM) [44] for 2 h prevented FGF2 from increasing IFNT mRNA abundance (Fig. 2A) . Constitutive concentrations of IFNT mRNA were not affected REGULATION OF IFNT EXPRESSION BY PRKCD by calphostin C treatment, but FGF2 induction of IFNT mRNA was blocked (P , 0.05) in cells exposed to calphostin C.
In a follow-up study, PMA, a phorbol ester commonly used to activate the PKC pathway, was used to determine if FGF2 effects in CT1 cells could be replicated by DAG activation (Fig. 2B) . Supplementation with 100 nM PMA for 22-24 h increased (P , 0.05) IFNT mRNA abundance in CT1 cells to the same degree as FGF2 (Fig. 3B) . Combining FGF2 and PMA did not have additive or synergistic effects on IFNT mRNA concentrations.
A subsequent set of studies was completed to define the PKC subtype utilized by FGF2 and PMA in CT1 cells. Two pharmacological inhibitors were tested: Gö6976, an inhibitor of classical PKCs (a, b, and c) [45] , and rottlerin, an inhibitor of PRKCD and PRKCQ [46] [47] [48] (Fig. 3) . Pretreatment with Gö6976 for 2 h at a concentration that effectively inhibits classical PKC isoforms in other cells (5 lM) did not affect basal, FGF2-induced, or PMA-induced IFNT mRNA levels in CT1 cells (Fig. 3, A and B) . By contrast, FGF2 and PMA responses were inhibited (P , 0.05) after a 2-h exposure to rottlerin (Fig. 3, C and D) . Rottlerin did not affect constitutive IFNT mRNA concentrations. Also, rottlerin had no effect on tcRNA quality and quantity, 18S RNA concentrations, or rate of apoptosis (as determined by TUNEL analysis) (data not shown).
A subsequent experiment was completed to determine if rottlerin also affected the amount of IFNT protein secreted into conditioned CT1 medium after FGF2 or PMA treatment (Fig.  4) . IFNT protein concentration was determined by examining the antiviral activity of conditioned medium. Both FGF2 and PMA increased (P , 0.001) the antiviral activity of CT1 conditioned medium (Fig. 4) . Furthermore, preincubation with rottlerin prevented the FGF2 and PMA effects without affecting basal antiviral activities (Fig. 4) .
The FGF2-and rottlerin-dependent effects on IFNT mRNA concentrations were extended to Vivot cells and primary trophoblast outgrowths to examine whether the effects noted were also apparent in other cell models for bovine trophoblast. Both trophoblast cell systems examined in the present study responded similarly to FGF2 and rottlerin (Fig. 5) . Exposure to FGF2 increased (P , 0.05) IFNT mRNA abundance, and this A) Western blot analysis was completed to determine whether FGF2 affected MAPK3/1 phosphorylation status and to assess how U0126 (10 lM) affected MAPK3/1 phosphorylation status. Cells were exposed either to inhibitor (U0126) or the carrier (DMSO) for 2 h, then harvested either immediately before FGF2 supplementation (0 min) or at specific times after FGF2 treatment (5-120 min). Estimates of phosphorylated (p) MAPK3/1 and total MAPK3/1 concentrations were determined using Western blotting. Three replicate studies were completed, and representative blots are provided. B) The effect of MAP2K inhibition on basal-and FGF2-induced IFNT mRNA abundance was examined by exposing CT1 cells to each inhibitor for 2 h, then changing medium and incubating in the presence or absence of FGF2 for 24 h. Total cellular RNA was isolated, and quantitative RT-PCR (qRT-PCR) was used to determine the relative abundance of IFNT mRNA. 18S RNA was used as the internal control. These qRT-PCR data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 3 replicates). Significant differences (P , 0.05) are denoted by different lowercase letters.
FIG. 2. PKC-dependent systems regulate IFNT mRNA levels in CT1 cells.
A) The role of PKC in regulating FGF2-dependent increases in IFNT mRNA levels was examined by exposing CT1 cells to calphostin C (0.5 lM) or its carrier (DMSO) for 2 h. Cells were then incubated with or without FGF2 for 24 h. B) A separate experiment was completed to determine if exposure to PMA mimicked the effect of FGF2 in CT1 cells. Cells were incubated in the presence or absence of FGF2 and/or PMA for 24 h. In both experiments, tcRNA was isolated at the end of the incubation period, and quantitative RT-PCR was used to determine the relative abundance of IFNT mRNA. 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 4 replicates within each panel). Significant differences (P , 0.05) are denoted within each panel by different lowercase letters.
effect was abolished (P , 0.05) with prior exposure to rottlerin.
PRKCD Expression and Activation in Trophectoderm
A series of experiments were completed to identify the PKC target for rottlerin in CT1 cells and verify that FGF2 activates this target. Initially, the presence or absence of PRKCD and PRKCQ mRNA was determined using end-point RT-PCR (Fig.  6A) . PRKCD amplicons were identified in CT1 cells, Day 14 and Day 17 bovine conceptuses, and CL (positive control). In other work, PRKCD mRNA also was identified in Vivot cells, bovine blastocysts, and bovine primary trophoblast outgrowths (data not shown).
The PRKCQ mRNA was detected in CT1 cells, Day 14 and Day 17 conceptuses, and CL (Fig. 6A) , but the intensity of this product was lower than that for PRKCD in CT1 and Day 17 conceptuses. When using quantitative RT-PCR, the relative amounts of PRKCD mRNA were 89.8-6 7.3-fold greater than the concentration of PRKCQ mRNA in CT1 cells.
The ability of FGF2 to mediate PRKCD activity was examined by determining if FGF2 affected the phosphorylation status of PRKCD (Fig. 6B) . FGF2 supplementation increased phosphorylation of Y311 within 30 min and sustained this effect for at least 2 h in CT1 cells. This phosphorylation event is important for PRKCD activation in several cell systems [49] . Also, PMA mimicked the effects of FGF2 and increased Y311 phosphorylation status in CT1 cells (Fig. 6B) .
Impact of PRKCD Knockdown on Vivot Cell Responsiveness to FGF2
To establish the involvement of PRKCD in mediating FGF2 effects on IFNT mRNA production, RNA interference was used (Fig. 7) . Sufficient amounts of siRNA could not be transfected into CT1 cells to impact overall PRKCD mRNA abundance (data not shown). However, Vivot cells could be transfected well enough to reduce PRKCD mRNA concentrations by approximately 70% when using a cocktail of three PRKCD siRNAs (Fig. 7A) . PRKCD protein abundance also was decreased in Vivot cells exposed to the PRKCD siRNA cocktail (Fig. 7B) . The PRCKD siRNA cocktail did not affect constitutive concentrations of IFNT mRNA. However, cells containing the PRCKD siRNA were less able to respond to FGF2 than were those containing the control siRNA (Fig. 7) . FGF2 supplementation increased (P , 0.05) IFNT mRNA abundance in cells containing the control siRNA but not in cells containing the PRCKD siRNA. The IFNT mRNA response in these cells was not statistically different from that of the FGF2-and non-FGF2-treated controls.
PRKCD Regulates IFNT Expression Through MAPK3/ 1-Independent Pathways
The PRKCD regulates the activity of various downstream signaling molecules, including MAPK3/1 [50, 51] . Previous findings indicated that FGF2 supplementation did not increase MAPK3/1 phosphorylation status in CT1 cells (Fig. 1) , and a set of follow-up experiments were completed to determine whether MAPK3/1 was required for PRKCD-mediated effects on IFNT mRNA abundance (Fig. 8) . The first experiment was designed to examine whether rottlerin treatment altered MAPK3/1 phosphorylation status in CT1 cells (Fig. 8A) . No changes in the phosphorylation status of MAPK3/1 were evident after 2 h of exposure to rottlerin.
A subsequent experiment was completed to determine if ITS serum substitute used in the serum-free medium formulation affected MAPK3/1 phosphorylation status in CT1 cells. Cells cultured in serum-free medium without ITS for 24 h still exhibited pronounced basal phospho-MAPK3/1 and remained unresponsive to FGF2 challenge (Fig. 8B, left) . A subset of CT1 cells also were treated with 100 nM PD173074, a pharmacological inhibitor of FGFRs, before exposure to FGF2 (Fig. 8B, right) . No changes in phosphorylation status were detected before or after FGF2 challenge in cells exposed to this inhibitor.
Because slight modifications in MAPK3/1 phosphorylation status may go unnoticed in Western blot analyses, the MAPK3/1 inhibitor, PD98059 (25 nM), also was used to further examine whether FGF2 utilizes MAPK3/1 to regulate   FIG. 3 . Examination of how isoform-specific PKC inhibitors affect FGF2-induced IFNT expression in CT1 cells. A series of experiments were completed with CT1 cells to determine whether an inhibitor of classical PKCs (Gö 6976, 5 lM) or PRKCD (rottlerin, 5 lM) influence FGF2-and PMAdependent increases in IFNT mRNA levels. Cells were provided with inhibitors for 2 h, and then medium was replaced with medium containing or lacking FGF2 or PMA. Treatments included Gö 6976 and FGF2 (A), Gö 6976 and PMA (B), rottlerin and FGF2 (C), and rottlerin and PMA (D). After 24 h of exposure to FGF2 or PMA, tcRNA was isolated, and quantitative RT-PCR was used to determine the relative abundance of IFNT mRNA. 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 3 replicates within each panel). Significant differences (P , 0.05) are denoted within each panel by different lowercase letters.
REGULATION OF IFNT EXPRESSION BY PRKCD
IFNT mRNA abundance in CT1 cells (Fig. 8C) . Unlike the MAP2K inhibitor, U0126, which targets both active and inactive MAP2K1/2, PD98059 functions primarily to prevent phosphorylation of inactive MAP2K1/2 [52] . Exposure to this inhibitor did not affect basal levels of MAPK3/1 phosphorylation (Fig. 8C) , and the ability of FGF2 to increase IFNT mRNA concentrations was not impeded using this inhibitor (Fig. 8D) .
DISCUSSION
The present results provide evidence that PKCs, and specifically PRKCD, mediate FGF2-induced production of IFNT. An examination of IFNT mRNA abundance was used to describe these changes. Previous work by this laboratory and others determined that the relative abundance of IFNT mRNA is directly associated with IFNT protein concentrations in trophoblast cell lysates and conditioned medium [28, 29, 53, 54] . No direct evidence that FGF2 impacted IFNT transcription was found in the present study. IFNT promoter/enhancer reporter constructs were not used because the bovine trophoblast cell lines in the present study were difficult to transfect with calcium phosphate precipitation and commercially available lipid-and amine-based transient transfection reagents (Yang and Ealy, unpublished observations). Unpublished work from this laboratory has determined that maximal increases in IFNT mRNA abundance are evident after 6-8 h of exposure to FGFs, suggesting that FGF2 and other FGFs manipulate IFNT transcription rates. However, it remains possible that FGF2 may also control IFNT mRNA concentrations by mediating RNA stability. Additional work is required to describe the precise transcriptional and posttranscriptional steps influenced by FGF2 in bovine trophoblast cells.
Various PKCs are linked to preimplantation embryo development. From 7 to 10 PKC isotypes are expressed in mouse embryos [55] [56] [57] [58] . Various PKC isoforms also are expressed in human placentae [59] . In this work, PKCdependent regulation of IFNT mRNA abundance initially was established by inhibiting PKC activity with calphostin C and stimulating PKC activity with PMA. Basal concentrations of IFNT mRNA were unaffected by calphostin C supplementation, indicating low endogenous PKC activity in these cells, but this inhibitor prevented FGF2 from increasing IFNT mRNA levels in bovine cells. PMA supplementation stimulated IFNT mRNA and protein production in CT1 cells. Others have linked PKC activity with IFNT production in ovine trophectoderm. Adding PMA increased IFNT mRNA concentrations, and calphostin C treatment abolished CSF2-mediated increases in FIG. 5. Rottlerin prevents FGF2 from increasing IFNT mRNA levels in two additional bovine trophoblast cell systems. Vivot cells (A) and primary trophoblast outgrowths (B) were exposed to rottlerin or its carrier control for 2 h, then cultured with exposure to FGF2 or BSA (control). After 24 h, tcRNA was isolated, and quantitative RT-PCR was used to determine the relative abundance of IFNT mRNA. 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 3 replicates within each panel). Significant differences (P , 0.01) are denoted within each panel with different lowercase letters.
FIG. 4. Rottlerin prevents FGF2
or PMA from increasing IFNT protein concentrations in conditioned CT1 medium. CT1 cells were serum-starved for 24 h, then treated with 5 lM rottlerin or vehicle (DMSO). After 2 h, medium was removed and replaced with medium containing 0 or 50 ng/ ml of FGF2 (A) or 0 or 10 nM PMA (B). After 48 h, conditioned medium was harvested, and antiviral assays were used to determine IFNT secretion. Antiviral results (IU/ml conditioned medium) were normalized based on viable cell number (measuring the amount of tetrazolium oxidation; A 490 readings). Data are presented as IU/ml conditioned medium as normalized for cell titer readings (A 490 ; mean 6 SEM, n ¼ 5 replicates within each panel). Significant differences (P , 0.01) are denoted within each panel with different lowercase letters.
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IFNT mRNA concentrations in ovine conceptus explants [37] . In addition, reporter plasmids containing 5 0 untranslated regions of the IFNT promoter/enhancer were stimulated in JEG3 human choriocarcinoma cells treated with PMA [38, 60] .
Additional PKC inhibitors were used to identify the specific PKC isoform employed by FGF2 to control IFNT expression in bovine trophoblast cells. Atypical PKCs were not examined, because these kinases are not responsive to PMA and other phorbol esters [39] . Exposing CT1, Vivot, and bovine trophoblast outgrowths to the PRKCD inhibitor, rottlerin, blunted FGF2-induced increases in IFNT mRNA levels. Rottlerin also blocked FGF2 and PMA from increasing IFNT protein concentrations in conditioned medium. Rottlerin effectively inhibits PRKCD in other cell types at concentrations used in the present work (effective range, 3-6 lM) [47] . Preliminary studies found that rottlerin was partially effective at blocking FGF2 responses in CT1 cells at 1 lM but that the 5 lM treatment provided full inhibition of this response. Rottlerin also inhibits other kinases. Notably, it blocks the activity of PRKCQ, another novel PKC, when used at 10-20 lM [48, 61] . PRKCQ expression is less widespread throughout tissues and primarily is studied regarding platelet activation and T-cell function [39] . It is present in CT1 cells, but its level of expression is substantially less than that of PRKCD. Exposing CT1 cells to Gö6976, an inhibitor of classical PKC molecules (a, b, and c), did not affect the ability of FGF2 to stimulate IFNT mRNA levels in CT1 cells. A single concentration of this inhibitor was examined herein (5 lM), and although this concentration has blocked classic PKC activity in other cells [45] , no attempts were made in the present study to verify its effectiveness in CT1 cells. Therefore, the role of classic PKCs B) The ability of FGF2 or PMA to affect PRKCD phosphorylation status at Y311 was examined by Western blot analysis. CT1 cell lysates were collected either immediately before (0 min) or at specific periods (30-120 min) after treatment with 50 ng/ml of FGF2 or 100 nM PMA. Lysates were electrophoresed, blotted onto PVDF membrane, and immunoblotted with antibodies recognizing phosphorylated Y311 within PRKCD. Three replicate studies were completed, and a representative blot is provided. A single immunoreactive band of the correct molecular mass was observed in all blots. Blots were stripped and reused to detect the relative amounts of a-tubulin to ensure appropriate sample loading.
FIG. 7.
The siRNA knockdown of PRKCD mRNA and protein in trophoblast cells impacts the ability of FGF2 to increase IFNT mRNA levels. Vivot cells were transfected with a mix of three PRKCD-specific siRNAs (25 nM each, 75 nM total) or negative-control siRNA (NC). Transfection medium was replaced after 9 h. A) The relative abundance of PRKCD mRNA was determined. At 60 h posttransfection, cells were cultured in the presence or absence of FGF2 for 24 h. Total cellular RNA was isolated and used for quantitative RT-PCR (qRT-PCR). 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 4 replicates). B) Relative amounts of PRKCD were determined by Western blot analysis. At 72 h posttransfection, cell lysates were electrophoresed, blotted onto a PVDF membrane, and examined with a polyclonal, non-phosphorylation-specific PRKCD antibody. A single protein band of the correct size was detected in each of three independent studies. Also, a visual reduction in the intensity of the PRKCD band was observed in each study. A representative Western blot is provided. Blots were stripped and reused to detect the relative amounts of a-tubulin to ensure similar sample loading. C) The relative abundance of IFNT mRNA was determined after FGF2 challenge. At 60 h posttransfection, cells were cultured in the presence or absence of FGF2 for 24 h. Total cellular RNA was isolated and used for qRT-PCR. 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 4 replicates). In A and C, significant differences (P , 0.05) are denoted within each panel by different lowercase letters.
REGULATION OF IFNT EXPRESSION BY PRKCD
on regulation of IFNT gene expression cannot be discounted based on the present findings.
The involvement of PRKCD in FGF2-mediated effects on trophoblast cells was confirmed by RNA interference. Difficulties in obtaining high-efficiency transfection precluded using CT1 cells for siRNA studies. However, a contemporary trophoblast cell line derived from an in vivo-generated blastocyst (Vivot line) could be transfected with moderate efficiency, and reductions in PRKCD mRNA and protein concentrations were associated with diminished FGF2 effects on IFNT mRNA concentrations. The siRNA treatment did not generate a complete loss in FGF2-induced effects in Vivot cells. This likely reflects limitations in the knockdown efficiency of PRKCD mRNA and PRKCD protein. Both were still evident after transfection. It remains possible that additional PKCs, such as PRKCQ, may also be involved with mediating FGF2 actions, but observing a partial reduction in FGF2-mediated events after PRKCD siRNA treatment provides conclusive evidence that PRKCD is one of the signaling molecules involved with this process.
Best known as a regulator of apoptosis, PRKCD is a widely expressed, multifunctional kinase [62, 63] . However, it also can promote cell survival in some instances [62, 63] . Moreover, it contains apposing activities in terms to cell proliferation and tumorigenesis [62, 64] . Several reports have described how PRKCD regulates peri-implantation embryo development and trophoblast function. PRKCD is detected throughout early embryo development in mice [55] . It associates with the spindle apparatus during meiosis and localizes to the nucleus, where it regulates mRNA processing, during initial cleavage events [65, 66] . At the blastocyst stage, PRKCD localizes primarily to the plasma membrane in trophoblast cells and is a central regulator of tight junction formation and ion transport during blastocoel formation [56, 67] .
The PMA responses observed in the present study are consistent with previous descriptions of PMA effects on ovine IFNT transcription [37, 38, 60, 68] . Both PMA and FGF2 likely affect IFNT mRNA abundance in bovine trophoblast cells by acting through PRKCD. No additive or synergistic effects were noted upon FGF2 and PMA cotreatment, and rottlerin effectively blocked the ability of both FGF2 and PMA to stimulate IFNT mRNA levels in various bovine trophoblast cell lines. However, PRKCD probably is not the only signaling molecule impacted by PMA in trophoblast cells. Phorbol esters are best known for their ability to stimulate DAG-mediated events, but many of these agents, including PMA, interact with non-PKC targets [39] . This is especially germane when considering previous work using JEG3 cells to study IFNT promoter/enhancer activity. JEG3 cells lack PRKCD [69] (unpublished observations), yet PMA treatment stimulated promoter/enhancer activity in this and other human cell lines [38, 60, 68] . Therefore, it appears that PMA acts on PRKCD to impact IFNT transcription and/or RNA stability in homologous cell systems but acts on different signaling molecules in heterologous systems to regulate IFNT expression.
The PRKCD can impact a variety of downstream signaling molecules. Several examples of FGF-induced PRKCD activation events that subsequently impact MAPK3/1 activity have been reported [50, 51] . Activation of MAPK3/1 did not appear FIG. 8. MAK3/1-dependent systems are not required for FGF2-dependent increases in IFNT mRNA abundance. A) Western blot analysis was completed to determine whether rottlerin affected MAPK3/1 phosphorylation status in the presence or absence of FGF2. Cells were exposed to rottlerin (5 lM) for 2 h, then harvested either immediately before FGF2 supplementation (0 min) or at specific times (5-120 min) after FGF2 treatment. Estimates of phosphorylated (p) MAPK3/1 and total MAPK3/1 concentrations were determined by Western blotting. Three replicate studies were completed, and representative blots are provided. B) Western blot analysis was conducted to determine whether ITS supplementation or the activity of endogenous FGFs influenced basal and FGF2 MAPK3/1 phosphorylation status. CT1 cells were culture in serum-free medium without ITS in the presence or absence of FGFR inhibitor PD173074 (100 nM) for 24 h. Cells were harvested either immediately before FGF2 supplementation (0 min) or at specific times (5-120 min) after FGF2 treatment. Estimates of phosphorylated (p) MAPK3/1 and total MAPK3/1 concentrations were determined by Western blotting. C) Western blot analysis was completed to determine whether FGF2 affected MAPK3/1 phosphorylation status and to assess how PD98059 (25 lM) affected MAPK3/1 phosphorylation. Cells were exposed to inhibitor and FGF2 as described in A. Three replicate studies were completed, and representative blots are provided. D) The effect of MAP2K inhibition on basal and FGF2-induced IFNT mRNA abundance was examined by exposing CT1 cells to PD98059 for 2 h, then changing medium and incubating in the presence or absence of FGF2 for 24 h. Total cellular RNA was isolated, and quantitative RT-PCR was used to determine the relative abundance of 3 IFNT mRNA. 18S RNA was used as the internal control. Data are presented as fold-differences (mean 6 SEM) from the control value (n ¼ 3 replicate studies). Significant differences (P , 0.05) are denoted with different lowercase letters.
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to be required for FGF2 to increase IFNT mRNA abundance in the present study. Rottlerin did not influence MAPK3/1 phosphorylation status. Also, preventing MAPK3/1 phosphorylation with PD98059, an inhibitor that limits phosphorylation of MAPK3/1 without affecting the activity of previously phosphorylated MAPK3/1, did not affect the ability of FGF2 to increase IFNT mRNA levels. However, abolishing all of the active MAPK3/1 in CT1 cells with U0126 (including constitutively active molecules) dramatically decreased IFNT mRNA abundance, and FGF2 supplementation was not effective at increasing IFNT mRNA abundance in the absence of activated MAPK3/1. This suggests that MAPK3/1 is requisite for basal IFNT transcription. It must be noted, however, that FGF2 studies were completed over a 22-to 24-h time period, whereas effects of the inhibitors on MAPK3/1 activity were only examined for the first 2 h of this period. Therefore, the possibility that FGF2 affected MAPK3/1 activity after 2 h from the beginning of FGF2 treatment cannot be discounted. It also remains unknown how long the inhibitors blocked MAPK3/1 activity in these studies. Therefore, MAPK3/1 does not appear to be directly involved with transducing the FGF2 signal, but these molecules do appear to be essential for basal responses in CT1 cells. The direct control of IFNT transcription by RAS-dependent pathways has been reported by others [26] . In that work, MAPK-dependent systems impacted ETS2 activity. It also is possible that RAS-MAPK affects other transcriptional regulators of IFNT. In mice, MAPK controls Cdx2 expression in preimplantation embryos [70] . This trophectoderm specification factor is a central component of IFNT promoter/enhancer activity [27] .
It was interesting to note that CT1 cells and Vivot cells (data not shown) contained ample amounts of phosphorylated MAPK3/1 before FGF2 administration. Constitutive phosphorylation of MAPK3/1 also exists in mouse trophoblast cells, and MAPK3/1 activity is essential for trophoblast development and differentiation in this species [70] [71] [72] . Endogenous MAPK3/1 activity could not be reduced by removing the serum substitute from cultures (ITS). Also, blocking endogenous FGFs with a pharmacological inhibitor to FGFRs did not influence constitutive phosphorylation of MAPK3/1.
To conclude, based on the present results, it is reasonable to propose that PRKCD acts as a signaling module for uterineand conceptus-derived FGFs and, potentially, other molecules in periattachment bovine conceptuses. Several uterine-derived factors, including multiple FGFs, can increase IFNT production in ovine and bovine trophoblast cells. Moreover, several FGFs are produced by conceptuses throughout pre-and periattachment development coincident with maximal IFNT production [28] . The present study provides new insight regarding how uterine-and conceptus-derived factors impact conceptus development and gene expression during pre-and periattachment development. Further exploration is needed to understand the full extent of PRKCD activities during periattachment development in bovine conceptuses.
